These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 31113871)

  • 1. As a downstream target of the AKT pathway, NPTX1 inhibits proliferation and promotes apoptosis in hepatocellular carcinoma.
    Zhao Y; Yu Y; Zhao W; You S; Feng M; Xie C; Chi X; Zhang Y; Wang X
    Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31113871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. microRNA-1914, which is regulated by lncRNA DUXAP10, inhibits cell proliferation by targeting the GPR39-mediated PI3K/AKT/mTOR pathway in HCC.
    Sun L; Wang L; Chen T; Yao B; Wang Y; Li Q; Yang W; Liu Z
    J Cell Mol Med; 2019 Dec; 23(12):8292-8304. PubMed ID: 31576658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carboxypeptidase A6 Promotes the Proliferation and Migration of Hepatocellular Carcinoma by Up-regulating AKT Signaling Pathway.
    Huang QB; Zhang HW; Liao ZB
    Curr Med Sci; 2019 Oct; 39(5):727-733. PubMed ID: 31612389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LncRNA CDKN2B-AS1 promotes tumor growth and metastasis of human hepatocellular carcinoma by targeting let-7c-5p/NAP1L1 axis.
    Huang Y; Xiang B; Liu Y; Wang Y; Kan H
    Cancer Lett; 2018 Nov; 437():56-66. PubMed ID: 30165194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LINC00707 promotes hepatocellular carcinoma progression through activating ERK/JNK/AKT pathway signaling pathway.
    Wang J; Luo Z; Yao T; Li W; Pu J
    J Cell Physiol; 2019 May; 234(5):6908-6916. PubMed ID: 30317590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ERCC6L promotes the progression of hepatocellular carcinoma through activating PI3K/AKT and NF-κB signaling pathway.
    Chen H; Wang H; Yu X; Zhou S; Zhang Y; Wang Z; Huang S; Wang Z
    BMC Cancer; 2020 Sep; 20(1):853. PubMed ID: 32891122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target.
    Chen H; Wong CC; Liu D; Go MYY; Wu B; Peng S; Kuang M; Wong N; Yu J
    Theranostics; 2019; 9(18):5246-5260. PubMed ID: 31410213
    [No Abstract]   [Full Text] [Related]  

  • 8. STK17B promotes carcinogenesis and metastasis via AKT/GSK-3β/Snail signaling in hepatocellular carcinoma.
    Lan Y; Han J; Wang Y; Wang J; Yang G; Li K; Song R; Zheng T; Liang Y; Pan S; Liu X; Zhu M; Liu Y; Meng F; Mohsin M; Cui Y; Zhang B; Subash S; Liu L
    Cell Death Dis; 2018 Feb; 9(2):236. PubMed ID: 29445189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AGBL2 promotes cancer cell growth through IRGM-regulated autophagy and enhanced Aurora A activity in hepatocellular carcinoma.
    Wang LL; Jin XH; Cai MY; Li HG; Chen JW; Wang FW; Wang CY; Hu WW; Liu F; Xie D
    Cancer Lett; 2018 Feb; 414():71-80. PubMed ID: 29126912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined inhibition of AURKA and HSF1 suppresses proliferation and promotes apoptosis in hepatocellular carcinoma by activating endoplasmic reticulum stress.
    Shen Z; Yin L; Zhou H; Ji X; Jiang C; Zhu X; He X
    Cell Oncol (Dordr); 2021 Oct; 44(5):1035-1049. PubMed ID: 34176092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NCSTN promotes hepatocellular carcinoma cell growth and metastasis via β-catenin activation in a Notch1/AKT dependent manner.
    Li H; Lan T; Xu L; Liu H; Wang J; Li J; Chen X; Huang J; Li X; Yuan K; Zeng Y; Wu H
    J Exp Clin Cancer Res; 2020 Jul; 39(1):128. PubMed ID: 32631394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clusterin facilitates metastasis by EIF3I/Akt/MMP13 signaling in hepatocellular carcinoma.
    Wang C; Jin G; Jin H; Wang N; Luo Q; Zhang Y; Gao D; Jiang K; Gu D; Shen Q; Huo X; Hu F; Ge T; Zhao F; Chu W; Shu H; Yao M; Cong W; Qin W
    Oncotarget; 2015 Feb; 6(5):2903-16. PubMed ID: 25609201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
    Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
    Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small nucleolar RNA ACA11 promotes proliferation, migration and invasion in hepatocellular carcinoma by targeting the PI3K/AKT signaling pathway.
    Wu L; Zheng J; Chen P; Liu Q; Yuan Y
    Biomed Pharmacother; 2017 Jun; 90():705-712. PubMed ID: 28419966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The tumor suppressor DLC1 inhibits cancer progression and oncogenic autophagy in hepatocellular carcinoma.
    Wu HT; Xie CR; Lv J; Qi HQ; Wang F; Zhang S; Fang QL; Wang FQ; Lu YY; Yin ZY
    Lab Invest; 2018 Aug; 98(8):1014-1024. PubMed ID: 29785050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NMI promotes hepatocellular carcinoma progression via BDKRB2 and MAPK/ERK pathway.
    Zhao J; Dong QZ; Zhong F; Cai LL; Qin ZY; Liu Y; Lin CZ; Qin LX; He FC
    Oncotarget; 2017 Feb; 8(7):12174-12185. PubMed ID: 28077802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DEP domain containing 1 predicts prognosis of hepatocellular carcinoma patients and regulates tumor proliferation and metastasis.
    Qu D; Cui F; Lu D; Yang Y; Xu Y
    Cancer Sci; 2019 Jan; 110(1):157-165. PubMed ID: 30417471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of UBE2Q1 via gene copy number gain in hepatocellular carcinoma promotes cancer progression through β-catenin-EGFR-PI3K-Akt-mTOR signaling pathway.
    Zhang B; Deng C; Wang L; Zhou F; Zhang S; Kang W; Zhan P; Chen J; Shen S; Guo H; Zhang M; Wang Y; Zhang F; Zhang W; Xiao J; Kong B; Friess H; Zhuge Y; Yan H; Zou X
    Mol Carcinog; 2018 Feb; 57(2):201-215. PubMed ID: 29027712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hsa_circ_0070269 inhibits hepatocellular carcinoma progression through modulating miR-182/NPTX1 axis.
    Su X; Su J; He H; Zhan Y; Liu H
    Biomed Pharmacother; 2019 Dec; 120():109497. PubMed ID: 31606623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silencing of CDCA5 inhibits cancer progression and serves as a prognostic biomarker for hepatocellular carcinoma.
    Wang J; Xia C; Pu M; Dai B; Yang X; Shang R; Yang Z; Zhang R; Tao K; Dou K
    Oncol Rep; 2018 Oct; 40(4):1875-1884. PubMed ID: 30015982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.